VERAXA Biotech (NASDAQ: VRXA) announced the expansion of its research and development facilities in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will accommodate planned growth of the R&D team, installation of new laboratory equipment, and completion of infrastructure needed to advance future development activities.
The expansion aligns with the company's efforts to advance its growing portfolio of proprietary and partnered oncology programs from discovery-stage research toward early clinical development. VERAXA's pipeline is centered on its BiTAC platform, including BiTAC-TCE and BiTAC-ADC candidates, which are designed to enable tumor-restricted activation of cancer therapies through the use of complementary precursor molecules.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats.
For more details, the full press release is available at https://ibn.fm/n3t6U. The latest news and updates relating to VRXA can be found in the company's newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These risks are detailed in the company's filings with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.
